Advertisement
Screener

Stoke Therapeutics, Inc. (STOK) Lessee, Operating Lease, Liability, to be Paid, Year One

2.3 / 5 stars · 19/41 Roast Me

Stoke Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One

Stoke Therapeutics, Inc. (STOK) had Lessee, Operating Lease, Liability, to be Paid, Year One of $700.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-08-03

  • 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $700.00K.
  • 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $699.00K.
  • 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $3.25M.
  • 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $780.00K.
Period endLessee, Operating Lease, Liability, to be Paid, Year One
2026-06-30$700.00K
10-Q · filed 2026-08-03
2026-03-31$699.00K
10-Q · filed 2026-05-07
2025-12-31$3.25M
10-K · filed 2026-03-16
2025-09-30$780.00K
10-Q · filed 2025-11-04
2025-06-30$1.40M
10-Q · filed 2025-08-12
2025-03-31$2.17M
10-Q · filed 2025-05-13
2024-12-31$2.66M
10-K · filed 2025-03-18
2024-09-30$653.00K
10-Q · filed 2024-11-05
2024-06-30$1.31M
10-Q · filed 2024-08-07
2024-03-31$1.96M
10-Q · filed 2024-05-06
2023-12-31$2.61M
10-K · filed 2024-03-25
2023-09-30$634.00K
10-Q · filed 2023-11-07
2023-06-30$1.27M
10-Q · filed 2023-08-07
2023-03-31$1.90M
10-Q · filed 2023-05-04
2022-12-31$2.53M
10-K · filed 2023-03-06
2022-09-30$2.53M
10-Q · filed 2022-11-14
2022-06-30$2.53M
10-Q · filed 2022-08-08
2022-03-31$2.53M
10-Q · filed 2022-05-10
2021-12-31$2.12M
10-K · filed 2022-03-10
2021-09-30$2.12M
10-Q · filed 2021-11-08
2021-06-30$483.00K
10-Q · filed 2021-08-10
2021-03-31$81.00K
10-Q · filed 2021-05-10
2020-12-31$1.10M
10-Q · filed 2021-11-08
2020-09-30$1.10M
10-Q · filed 2020-11-12
2020-06-30$1.10M
10-Q · filed 2020-08-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Innoviva, Inc. (INVA)United States$1.493B4.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Xencor Inc (XNCR)United States$1.776B-7.33
Septerna, Inc. (SEPN)United States$1.783B-63.01